Skyrizi 150 mg solution for injection in pre-filled syringe clinical trials

A Phase 4 Mechanistic Longitudinal Study to Evaluate the Impact of EARLY Risankizumab Treatment on TRM Cell Levels in Moderate-to-Severe Psoriasis

This study looks at how an early treatment for moderate to severe psoriasis, called Skyrizi, affects certain cells in the skin. Researchers want to see if starting treatment sooner helps reduce these cells more effectively than starting later, and how clear the skin becomes.